

FURANODITERPENE GLUCOSIDES FROM *FIBRAUREA TINCTORIA*

HIDEJI ITOKAWA, KENJI MIZUNO, REIKO TAJIMA and KOICHI TAKEYA

Tokyo College of Pharmacy, Horinouchi, Hachioji, Tokyo 192-03, Japan

(Revised received 26 September 1985)

Key Word Index—*Fibraurea tinctoria*; Menispermaceae; furanoditerpenes; diterpeneglucosides; NMR; tinophyllolide; fibleucinoside; fibraurinoside; bitter principle.

Abstract—Two known furanoditerpenes, fibleucin and fibraurin, and three new furanoditerpene glucosides, tinophyllolide, fibleucinoside and fibraurinoside were isolated as bitter principles from the non-alkaloidal fraction of *Fibraurea tinctoria*. The structures were established by chemical and spectroscopic methods.

INTRODUCTION


The rhizomes of *Fibraurea tinctoria* Lour. are one of the important crude drugs in Chinese medicine, and have been used from ancient times as an antipyretic, antidote, diuretic and cathartic [1, 2]. Studies on the chemical constituents of *Fibraurea* plants afforded bitter-tasting alkaloids such as palmatine, jatrorrhizine and columbamine [1, 2], and diterpenes such as fibleucin (1) and fibraurin (2) [3, 4]. We have now isolated a further three novel bitter-tasting diterpene glucosides which we have named tinophyllolide (3), fibleucinoside (4) and fibraurinoside (5). This paper describes the structural elucidation of these new bitter principles.

RESULTS AND DISCUSSION


The aqueous solution of the methanol extract from the rhizomes of *F. tinctoria* was partitioned successively with chloroform and ethyl acetate, and each extract fractionated into its bitter-tasting components. When the chloroform extract was subjected to silica gel column chromatography, compounds 1 and 2 were obtained. Reversed column chromatography of the ethyl acetate extract gave three new bitter principles (3–5). Compounds

1 and 2 were identified as fibleucin and fibraurin respectively by comparison of their physical and spectral properties with those reported in the literature for these two diterpenes [3–7]. The structures were also supported by the ^1H and ^{13}C NMR spectral data (Tables 1 and 2). Each signal was assigned by known chemical shift rules, decoupling experiments and off-resonance decoupling techniques, etc. [8, 9].


Tinophyllolide (3), $\text{C}_{27}\text{H}_{36}\text{O}_{11}$, colourless powder, mp 155–158°, $[\alpha]_{\text{D}}^{21} -19.2^\circ$ showed an $[\text{M} + 1]^+$ ion at m/z 537 on secondary ion mass spectrometry (SIMS). Its IR spectrum showed the presence of hydroxyl groups (3440 cm^{-1}), a furan ring ($3160, 1510, 875\text{ cm}^{-1}$), a δ -lactone and an α,β -unsaturated ester carbonyl group (1730 and 1715 cm^{-1}). The ^1H NMR spectrum suggested the presence of β -substituted furan ring [$\delta 6.51$ (1H, *dd*, $J = 0.7$ and 1.7 Hz), 7.51 (1H, *t*, $J = 1.7\text{ Hz}$) and 7.59 (1H, *t*, $J = 0.7\text{ Hz}$)], two tertiary methyl groups ($\delta 0.97$ and 1.41), one methoxy-methyl group ($\delta 3.75$) and one olefinic proton [$\delta 6.45$ (1H, *d*, $J = 3.8\text{ Hz}$)]. The signal pattern was similar to that of tinophyllone (6) [10, 11], however, the olefinic proton at $\delta 6.45$ was coupled ($J = 3.8\text{ Hz}$) with the proton at $\delta 4.69$ (1H, *dt*, $J = 3.8$ and 8.4 Hz), which was further coupled ($J = 8.4\text{ Hz}$) with the C-1 protons at $\delta 2.31$. In addition glucosyl proton signals [$\delta 3.15$ – 3.87 and



R
1 H Fibleucin
4 O - Glc Fibleucinoside



R
2 H Fibraurin
5 O - Glc Fibraurinoside



R
3 H Tinophyllolide
6 O Tinophyllone

Table 1. ¹H NMR spectral data of the furanoditerpenes **1–5** [400 MHz, DMSO-*d*₆ (**1** and **2**) or CD₃OD (**3–5**), TMS as int. standard *J* (Hz) in parentheses]

H	1	2	3	4	5
1	5.36 (<i>dd</i> , 5.0, 2.0 Hz)	5.08 (<i>dd</i> , 3.0, 0.8 Hz)	1.26–1.40 (<i>m</i>) 2.23–2.39 (<i>m</i>)	5.37 (<i>dd</i> , 5.1, 1.5 Hz)	5.09 (<i>d</i> , 2.9 Hz)
2	6.53 (<i>dd</i> , 9.0, 5.0 Hz)	3.85 (<i>dd</i> , 4.5, 3.0 Hz)	4.69 (<i>td</i> , 8.4, 3.8 Hz)	6.64 (<i>dd</i> , 8.4, 5.1 Hz)	3.89 (<i>dd</i> , 4.5, 2.9 Hz)
3	6.34 (<i>dd</i> , 9.0, 2.0 Hz)	3.65 (<i>dd</i> , 4.5, 0.8 Hz)	6.45 (<i>d</i> , 3.8 Hz)	6.85 (<i>dd</i> , 8.4, 1.5 Hz)	4.26 (<i>d</i> , 4.5 Hz)
6	1.87 (<i>dd</i> , 16.0, 3.0 Hz)	1.64 (<i>dd</i> , 16.0, 2.5 Hz)	1.26–1.40 (<i>m</i>)	2.10 (<i>dd</i> , 16.3, 2.8 Hz)	1.98 (<i>dd</i> , 16.3, 3.0 Hz)
	2.42 (<i>dd</i> , 16.0, 8.0 Hz)	2.32 (<i>dd</i> , 16.0, 8.0 Hz)	2.57 (<i>dd</i> , 14.7, 3.0 Hz)	2.73 (<i>dd</i> , 16.3, 8.3 Hz)	2.59 (<i>dd</i> , 16.3, 8.4 Hz)
7	7.26 (<i>dd</i> , 8.0, 3.0 Hz)	7.23 (<i>dd</i> , 8.0, 2.5 Hz)	1.75 (<i>dd</i> , 13.4, 2.9 Hz) 2.23–2.39 (<i>m</i>)	7.43 (<i>dd</i> , 8.3, 2.8 Hz)	7.41 (<i>dd</i> , 8.4, 3.0 Hz)
8			2.78 (<i>dd</i> , 11.4, 2.9 Hz)		
10	1.67 (s)	1.77 (s)	1.90 (<i>br d</i> , 4.7 Hz)	1.77 (s)	1.91 (s)
11	1.98 (<i>dd</i> , 14.0, 12.0 Hz)	1.95 (<i>dd</i> , 14.0, 12.0 Hz)	1.99 (<i>dd</i> , 14.1, 11.4 Hz)	2.00 (<i>dd</i> , 14.0, 12.0 Hz)	2.00 (<i>dd</i> , 14.0, 12.0 Hz)
	2.34 (<i>dd</i> , 14.0, 2.0 Hz)	2.30 (<i>dd</i> , 14.0, 2.8 Hz)	2.14 (<i>dd</i> , 14.1, 5.8 Hz)	2.40 (<i>dd</i> , 14.0, 2.2 Hz)	2.37 (<i>dd</i> , 14.0, 1.8 Hz)
12	5.65 (<i>dd</i> , 12.0, 2.0 Hz)	5.64 (<i>dd</i> , 12.0, 2.8 Hz)	5.50 (<i>dd</i> , 11.4, 5.8 Hz)	5.72 (<i>dd</i> , 12.0, 2.2 Hz)	5.72 (<i>dd</i> , 12.0, 1.8 Hz)
14	6.62 (<i>dd</i> , 1.5, 1.0 Hz)	6.62 (<i>dd</i> , 1.5, 1.0 Hz)	6.51 (<i>dd</i> , 1.7, 0.7 Hz)	6.57 (<i>dd</i> , 1.8, 0.8 Hz)	6.57 (<i>dd</i> , 1.8, 0.8 Hz)
15	7.66 (t, 1.5 Hz)	7.66 (t, 1.5 Hz)	7.51 (t, 1.7 Hz)	7.51 (t, 1.8 Hz)	7.52 (t, 1.8 Hz)
16	7.74 (<i>dd</i> , 1.5, 1.0 Hz)	7.75 (<i>dd</i> , 1.5, 1.0 Hz)	7.59 (t, 0.7 Hz)	7.63 (t, 0.7 Hz)	7.63 (t, 0.8 Hz)
18	1.18 (s)	1.18 (s)	1.41 (s)	1.30 (s)	1.30 (s)
19	0.92 (s)	1.08 (s)	0.97 (s)	1.12 (s)	1.26 (s)
Ac			3.75 (s)		
anomeric H			4.45 (<i>d</i> , 7.8 Hz)	4.73 (<i>d</i> , 7.2 Hz)	4.82 (<i>d</i> , 7.3 Hz)

Table 2. ^{13}C chemical shifts of furanoditerpenes 1–5 [101 MHz, DMSO- d_6 (1 and 2) or CD_3OD (3–5), TMS as int. standard]

C	1	2	3	4	5
1	73.72 (d)	69.63 (d) ^c	27.07 (t)	75.45 (d)	71.36 (d) ⁱ
2	130.57 (d)	49.37 (d)	72.93 (d)	132.19 (d)	50.18 (d)
3	137.03 (d)	51.44 (d)	138.00 (d)	133.61 (d)	51.45 (d)
4	80.17 (s)	79.88 (s)	142.60 (s)	87.37 (s)	87.70 (s)
5	35.59 (s)	35.17 (s)	37.70 (s)	37.22 (s)	36.80 (s)
6	31.06 (t)	31.07 (t)	36.54 (t)	32.57 (t)	32.58 (t)
7	142.46 (d)	141.82 (d)	21.05 (t)	145.01 (d)	144.39 (d)
8	134.31 (s)	133.39 (s)	49.00 (d)	135.70 (s)	134.75 (s)
9	42.36 (s)	44.75 (s)	38.73 (s)	45.35 (s)	47.59 (s)
10	55.88 (d)	54.01 (d)	56.59 (d)	57.78 (d)	56.62 (d)
11	41.92 (t)	41.95 (t)	46.19 (t)	44.26 (t)	43.96 (t)
12	69.58 (d)	70.53 (d) ^c	71.60 (d)	71.42 (d)	72.29 (d) ⁱ
13	124.97 (s)	125.00 (s)	126.14 (s)	126.47 (s)	126.43 (s)
14	109.05 (d)	108.95 (d)	109.84 (d)	109.67 (d)	109.63 (d)
15	140.44 (d)	140.31 (d)	141.37 (d)	141.50 (d)	141.49 (d)
16	143.80 (d)	143.77 (d)	145.03 (d)	145.01 (d)	145.04 (d)
17	174.49 (s) ^a	171.33 (s) ^d	177.48 (s) ^f	174.87 (s) ^g	171.68 (s) ^j
18	26.36 (q) ^b	24.93 (q) ^e	34.04 (q)	27.18 (q) ^h	25.82 (q) ^k
19	20.31 (q) ^b	20.68 (q) ^e	23.54 (q)	21.36 (q) ^h	21.67 (q) ^k
20	163.07 (s) ^a	163.02 (s) ^d	170.18 (s) ^f	166.22 (s) ^g	166.15 (s) ^j
1'			103.66 (d)	101.54 (d)	101.80 (d)
2'			75.19 (d)	75.31 (d)	75.34 (d)
3'			78.21 (d)	78.41 (d)	78.41 (d)
4'			71.90 (d)	72.24 (d)	72.19 (d)
5'			78.03 (d)	78.15 (d)	78.41 (d)
6'			62.93 (t)	62.71 (t)	62.83 (t)
Ac			52.23 (q)		

^{a–k}Assignments may be reversed.

$\delta 4.45$ (1H, d, $J = 7.8$ Hz, anomeric H)] were present. Hydrolysis of **3** gave glucose (identified by GLC). From the above results, it is reasonable to conclude that **3** was tinophyllol 2- β -glucoside. This structure was also supported from the ^{13}C NMR data (Table 2).

Fibleucinoside (**4**), $\text{C}_{26}\text{H}_{30}\text{O}_{11}$, colourless needles, mp $187.5\text{--}189.0^\circ$, $[\alpha]_{\text{D}}^{21} + 1.0^\circ$; SIMS m/z : 519 $[\text{M} + 1]^+$, showed hydroxyl (3420 cm^{-1}), two δ -lactone carbonyl (1760 and 1710 cm^{-1}) and furan ring (3160 , 1620 , 1510 and 875 cm^{-1}) bands in the IR spectrum. Most of the ^1H and ^{13}C NMR signals of **4** were the same as to those of **1**, however, the C-4 carbon signal of **1** at $\delta 80.17$ was shifted downfield to $\delta 87.37$ and six additional carbon signals due to glucose were present. The coupling constant of the anomeric proton at $\delta 4.73$ was 7.2 Hz. Hydrolysis of **4** furnished compound **1** and glucose, which were identified by TLC and GLC. On the basis of the above data, **4** was determined as fibleucin 4- β -glucoside.

Fibraurinoside (**5**), $\text{C}_{26}\text{H}_{30}\text{O}_{12}$, colourless prism, mp $212\text{--}214.5^\circ$, $[\alpha]_{\text{D}}^{21} - 8.7^\circ$; SIMS m/z : 535 $[\text{M} + 1]^+$. Its IR spectrum was similar to that of **4** and indicated the presence of a furanoditerpene glucoside. The ^1H and ^{13}C NMR spectra data due to the B and C furan rings and glucose moiety of **5** were similar to those of **4**, however, the olefinic proton and carbon signals of ring A at $\delta 6.64$, 6.85 , 132.19 and 133.61 in **4** were shifted to $\delta 3.89$, 4.26 , 50.18 and 51.45 in **5**. These findings suggested that **5** was 2,3-epoxy-fibleucinoside. Hydrolysis of **5** gave compound **2** and glucose (TLC or GLC). When the ^{13}C chemical

shifts of **5** were compared with those of **2**, the C-4 signal of **2** at $\delta 79.88$ was found to have been shifted downfield to $\delta 87.70$ in **5**. Consequently, **5** was confirmed to be fibraurin 4- β -glucoside.

The new furanoditerpene glucosides, **3**, **4** and **5**, were much more bitter than the aglycones, **1** and **2**.

EXPERIMENTAL

General procedures. Mps (micro melting point apparatus): uncorr; ^1H (400 MHz) and ^{13}C NMR (101 MHz): DMSO- d_6 or CD_3OD , with TMS as the int. standard; CC: silica gel (Wakogel C-200 or Kieselgel 60) at amounts equivalent to 50–100 times the sample amount; prep. HPLC: glass 22 mm i.d. \times 30 cm CIG column (Kusano Scientific Co., Tokyo) packed with Wakogel LC-50H (50 μm , silica gel) or RP-18 (25–40 μm); TLC: 0.25 mm silica gel (60F₂₅₄, Merck) or RP-18 plates (F_{254s}, Merck). Spots were detected by UV light (254 nm) and Ehrlich reagent.

Plant material. The rhizomes of *F. tinctoria* used in this experiment were purchased in Hong Kong, July 1983. A small number of them are kept in our laboratory. The material was identified as *F. tinctoria* by comparing the TLC pattern of a MeOH extract of the rhizomes with those of authentic herbarium specimens of *F. tinctoria* and *Arcangelisia flava*, which had been cultivated at Tsukuba Medicinal Plant Research Station (Botanical garden director, Dr. M. Satake), National Institute of Hygienic Science, Japan. The TLC systems used were silica gel $\text{C}_6\text{H}_6\text{--EtOAc--}n\text{-PrOH--MeOH--EtNH}_2$ (8:4:2:1:1) [12] $\text{MeOH--H}_2\text{O--NH}_4\text{OH}$ 25% (8:1:1), $\text{EtOAc--iso-PrOH--H}_2\text{O}$

(40:40:25) and *n*-BuOH–AcOH–H₂O (4:1:1) [13]. The spots were detected under UV light (254 and 366 nm) and by spraying with Dragendorff's reagent.

Extraction and isolation. The crude drug (1.0 kg) was cut into pieces and extracted with MeOH (2 × 3 l). The following isolation was made with the guidance of the bitter taste. The concd MeOH extract (91.2 g) was partitioned (× 2) between H₂O (1.5 l) and CHCl₃ (1.5 l) and then (× 2) between H₂O and EtOAc (1.5 l). The CHCl₃ extract (19.6 g) was subjected CC on silica gel eluted with CHCl₃–MeOH. The fraction eluted with CHCl₃–MeOH (99:1) was subjected to HPLC on silica gel eluted with *n*-hexane–EtOAc (1:1). This gave 634 mg of **1**. Repeated recrystallizations of the CHCl₃–MeOH (49:1) eluate furnished 1031 mg of **2**. The EtOAc extract (2.3 g) was subjected to HPLC on silica gel using CHCl₃–MeOH (9:1) and C₆H₆–EtOAc–MeOH (3:2:1), and then HPLC on RP-18 using MeOH–H₂O (7:3). When the procedures were repeated a few times, 26.9 mg of **3**, 32.7 mg of **4** and 48.6 mg of **5** were isolated.

Compound 1. Colourless prisms, mp 172–174° (from CHCl₃–MeOH), $[\alpha]_D^{25} - 5.2^\circ$ (*c* 0.5; C₂₆H₃₀N); Calc. for C₂₆H₃₀O₆·1/5H₂O: C, 66.73; H, 5.71; O, 27.55. Found: C, 66.92; H, 5.66; O, 27.42%; EIMS *m/z* (rel. int.): no parent ion, 312 (6), 279 (3), 218 (43), 203 (100), 159 (27), 108 (44), 81 (33); IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3570 (OH), 3160, 1610, 1510, 875 (furan bands), 1740, 1720 (C=O), 1635 (C=C); UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm (ϵ): 208 (10 500), 230 (7350).

Compound 2. Colourless prisms, mp 282.0–282.5° (dec. from MeOH), $[\alpha]_D^{25} - 32.8^\circ$ (*c* 0.5; C₂₆H₃₀N); EIMS *m/z* (rel. int.): 372 [M]⁺ (54), 327 (2), 261 (9), 229 (8), 203 (22), 133 (76), 94 (100), 81 (59); HRMS: Calc. 372.1208. Found 372.1235; IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3490 (OH), 3160, 1605, 1510, 880 (furan bands), 1770, 1695 (C=O), 1635 (C=C); UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm (ϵ): 209 (9300), 230 (6420).

Compound 3. Colourless powder, mp 135–138° (from H₂O), $[\alpha]_D^{25} - 19.2^\circ$ (*c* 0.25, MeOH); Calc. for C₂₇H₃₆O₁₁·H₂O: C, 58.47; H, 6.90; O, 34.61. Found: C, 58.67; H, 6.73; O, 34.60%; SIMS *m/z*: 537 [M + 1]⁺; EIMS *m/z* (rel. int.): no parent ion, 374 (98), 358 (39), 342 (100); IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3440 (br OH), 3160, 1510, 875 (furan bands), 1730, 1715 (C=O); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm (ϵ): 210 (10 620).

Compound 4. Colourless needles, mp 187.5–189.0° (from H₂O), $[\alpha]_D^{25} + 1.0^\circ$ (*c* 0.2; MeOH); Calc. for C₂₆H₃₀O₁₁·H₂O: C, 58.20; H, 6.01; O, 35.78. Found: C, 58.15; H, 5.96; O, 35.89%; SIMS *m/z*: 519 [M + 1]⁺; EIMS *m/z* (rel. int.): no parent ion, 312 (8), 297 (3), 203 (23), 201 (28), 131 (37), 108 (100), 94 (33), 81 (48); IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3420 (br OH), 3160, 1620, 1510, 875 (furan bands), 1760, 1710 (C=O), 1635 (C=C); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm (ϵ): 207 (9350), 229 (6110).

Compound 5. Colourless prisms, mp 212.0–214.5° (from CHCl₃–MeOH), $[\alpha]_D^{25} - 8.7^\circ$ (*c* 0.28; MeOH); Calc. for C₂₆H₃₀O₁₂·3/4CHCl₃: C, 51.48; H, 4.96; O, 30.76; Cl, 12.78. Found: C, 51.49; H, 5.05; O, 30.87; Cl, 12.59%; SIMS *m/z*: 535 [M + 1]⁺; EIMS *m/z* (rel. int.): 372 (48), 327 (3), 261 (12), 229 (8), 203 (24), 133 (91), 94 (100), 81 (79); IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3420 (br OH), 3160, 1510, 878 (furan bands), 1775, 1703 (C=O), 1635 (C=C); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm (ϵ): 212 (8710), 230 (6760).

Hydrolysis of furanoditerpene glucosides. The sample (3 mg) was hydrolysed with 1 ml 10% HCl at 90° for 4 hr, then cooled. The reaction mixture was concd under a stream of N₂ and the residue was employed for TLC and GLC. TLC of the hydrolysate of **4** on silica gel developed with CHCl₃–MeOH (19:1) showed the presence of **1** (*R_f* 0.75) whilst **5** gave **2** (*R_f* 0.70). TLC of the hydrolysates of **3**, **4** and **5** on silica gel developed with *n*-BuOH–Me₂CO–H₂O (4:5:1) gave glucose (*R_f* 0.34). The residue was trimethylsilylated and subjected to GLC, which showed the presence of glucose (GLC conditions: 1.5% silicone SE-30, 3 mm × 2 m, column temp. 150°, N₂ 1.0 kg/cm²; *R_i* 10.4 min).

REFERENCES

- Chiang Su New Medical College (1977) *Dictionary of Chinese Crude Drug*, p. 443. Shanghai Scientific Technological Publisher (2nd Band), China.
- Schwarz, F. and Doehnert, A. (1966) *Pharmazie* **21**, 443.
- Ito, K. and Furukawa, H. (1969) *Chem. Commun.* 653.
- Hori, T., Kiang, A. K., Nakanishi, K., Sasaki, S. and Woods, M. C. (1967) *Tetrahedron* **23**, 2649.
- Overton, K. H., Weir, N. G. and Wylie, A. (1966) *J. Chem. Soc. (C)* 1482.
- Cheung, K. K., Melville, D., Overton, K. H., Robertson, J. M. and Sim, G. A. (1966) *J. Chem. Soc. (B)* 853.
- Kunii, T., Kagei, K., Kawakami, Y., Nagai, Y., Nezu, Y. and Sato, T. (1985) *Chem. Pharm. Bull. (Tokyo)* **33**, 479.
- Jackman, L. M. and Sternhell, S. (1969) *Application of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry*, 2nd edn. Pergamon Press, London.
- Stothers, J. B. (1972) *Carbon-13 NMR Spectroscopy*. Academic Press, New York.
- Aguilar-Santos, G. (1965) *Chem. Ind.* 1074.
- Brehm, L. and Hodder, O. J. R. (1971) *J. Chem. Soc. (C)* 2529.
- Ikuta, A. and Itokawa, H. (1983) *Shoyakugaku Zasshi* **37**, 195.
- Siwon, J., Thijs, C., Verpoorte, R. and Svendsen, A. B. (1978) *Pharm. Weekbl.* **113**, 1153.